Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab in MSI-H/dMMR Colorectal Cancer
NCT04258111Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in colorectal cancer (CRC), sponsored by Innovent Biologics. Started Aug 2020; status: terminated.
02
Drugs
IBI310
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04258111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258111.